Published in Cancer Detection and Prevention 2000; 24(Supplement 1).

Differential expression of genes that associated with tumorigenesis of rat prostate epithelial cells

HFS Huang PhD, MT Li, R Watson MD, RJ Irwin MD

Dept Surgery Section of Urology, UMD-New Jersey Medical School, Newark, NJ USA,

AIMS: The current study examined the expression of genes that associated tumorigenesis of rat prostate epithelial cells. METHODS: cDNA array technology was employed to compare the expression of genes between non-tumorigenic rat prostate epithelial cells (NRP152) and that in methyl nitrosourea-induced tumorigenic cells (NRP154). RESULTS: Of 1176 different rat cDNA transcripts compared, there were 35 genes which were at least 1.5 times higher in NRP154 cells than that in NRP152 cells. Specifically, the expression of CXC chemokine and tissue inhibitor of metalloproteinase-2 in NRP154 cells was 4.66 and 3.28 times higher, respectively, than that in NRP152 cells. In addition, a group of nerve-related genes including neurokinase A receptor, alpha 1C adrenergic receptor and NGF-induced protein A were also over-expressed in NRP154 cells. Testosterone treatment of NRP154 cells induced the expression of STAT-3 that was below detection in both cell lines without treatment, as well as in testosterone-treated NRP152 cells. These results suggest that products of these genes might be involved in tumorigenesis of rat prostate epithelial cells. On the other hand, there were more than 30 genes including 12 ribosomal proteins, 2 heat shock proteins, 4 lipid-related proteins and 5 nerve-related proteins or receptors were at least 50% lower in NRP154 cells compared to NRP152 cells. CONCLUSIONS: Current results identified the genes that were either over- or under-expressed in tumorigenic rat prostate epithelial cells. Further studies in the relationship between these genes and pathogenesis in prostate cancer may facilitate diagnosis and perhaps treatment of this disease.

KEY WORDS: prostate cancer, gene array.

For more information, contact

Paper presented at the International Symposium on Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators; Geneva, Switzerland; October 28 - 31, 2000; in the section on genetic risk assessment.